

DISCONTINUED TEST

NOTIFICATION DATE: 11/20/2024

EFFECTIVE DATE: 02/01/2025

Prostatic Acid Phosphatase (PAP)

On the effective date, Northwell Health Laboratories will discontinue in-house testing for prostatic acid phosphatase (PAP). This marker was first discovered in the 1930's and its clinical utility was to detect prostate cancer metastasis. It has been replaced by prostate specific antigen (PSA) in the 1980s which is much more sensitive for early detection and for monitoring response and disease progression in non-metastatic and metastatic prostate cancer. We are providing this communication with ample notice so you can baseline your patients to PSA.

Although a great deal of effort has gone into harmonization of PSA assays, please consider that with all tumor markers, results between different assays are not interchangeable.

Computer Interface Code: [PDM # 5900130](#)

Test Order: [PAP](#)

Recommended Alternative Tests:

Test Requirement/Parameters	Prostate Specific Antigen	Prostate Specific Antigen PSA Total and Free
Methodology	ECLIA	ECLIA
Submission/Container	Gold Top Tube (Gold)	Gold Top Tube (Gold)
Specimen Volume/Minimum Volume	1mL of serum	1 mL of serum
Computer Interface Code	PDM#5302500	PDM # 5302504
Test Order	PSA	PSAF

If you have any questions, please contact Client Services at (800) 472-5757.

